Positive margins after radical prostatectomy: Implications for failure and role of adjuvant treatment

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 531-541

  Swanson, Gregory P ^a   Lerner, Seth P ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Failure; Positive margins; Prognosis; Prostate cancer; Prostatectomy; Recurrence risk

Indexed keywords

DIETHYLSTILBESTROL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; MEDICAL LITERATURE; MEDLINE; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEMINAL VESICLES;

EID: 84879459843     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.06.007     Document Type: Review

References (88)

1. Hohenberger W., Weber K., Matzel K., et al. Standardized surgery for colonic cancer: Complete mesocolic excision and central ligation-technical notes and outcome. Colorectal Dis 2009, 11:354-364.
2. Cotlar A.M., Dubose J.J., Rose D.M. History of surgery for breast cancer: Radical to the sublime. Curr Surg 2003, 60:329-337.
3. Han M., Partin A.W., Chan D.Y., et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004, 171:23-26.
4. Hall G.S., Kramer C.E., Epstein J.I. Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol 1992, 16:315-324.
5. Sakr W.A., Wheeler T.M., Blute M., et al. Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer 1996, 78:366-368.
6. Srigley J.R., Amin M.B., Epstein J.I., et al. Members of the Cancer Committee, College of American Pathologists updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med 2006, 130:936-946.
7. Stamey T.A., Villers A.A., McNeal J.E., et al. Positive surgical margins at radical prostatectomy: Importance of the apical dissection. J Urol 1990, 143:1166-1172.
8. Pettus J.A., Weight C.J., Thompson C.J., et al. Biochemical failure in men following radical retropubic prostatectomy: Impact of surgical margin status and location. J Urol 2004, 172:129-132.
9. Fesseha T., Sakr W., Grignon D., et al. Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol 1997, 158:2176-2179.
10. Sofer M., Hamilton-Nelson K.L., Civantos F., et al. Positive surgical margins after radical retropubic prostatectomy: The influence of site and number on progression. J Urol 2002, 167:2453-2456.
11. Ohori M., Abbas F., Wheeler T.M., et al. Pathologic features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol 1999, 161:500-504.
12. Poulos C.K., Koch M.O., Eble J.N., et al. Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence. Cancer 2004, 101:1563-1568.
13. Aydin H., Tsuzuki T., Hernandez D., et al. Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology 2004, 64:551-555.
14. Pierorazio P.M., Epstein J.I., Humphreys E., et al. The significance of a positive bladder neck margin after radical prostatectomy: The American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. J Urol 2010, 183:151-157.
15. Blute M.L., Bostwick D.G., Bergstralh E.J., et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 1997, 50:733-739.
16. Yossepowitch O., Sircar K., Scardino P.T., et al. Bladder neck involvement in pathologic stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol 2002, 168:2011-2015.
17. Obek C., Sadek S., Lai S., et al. Positive surgical margins with radical retropubic prostatectomy: Anatomic site-specific pathologic analysis and impact on prognosis. Urology 1999, 54:682-688.
18. Dash A., Sanda M.G., Yu M., et al. Prostate cancer involving the bladder neck: Recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. Urology 2002, 60:276-280.
19. Eastham J.A., Kuroiwa K., Ohori M., et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology 2007, 70:965-969.
20. Smith RC, Partin AW, Epstein JI, et al. Extended follow-up of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 199;156(2 Pt 1):454-7.
21. Ohori M., Wheeler T.M., Kattan M.W., et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995, 154:1818-1824.
22. Barocas D.A., Han M., Epstein J.I., et al. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. Urology 2001, 58:746-751.
23. Shuford M.D., Cookson M.S., Chang S.S., et al. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol 2004, 172:119-123.
24. Epstein J.I. Pathologic assessment of the surgical specimen. Urol Clin North Am 2001, 28:567-594.
25. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:110-114.
26. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523.
27. Salomon L., Levrel O., Anastasiadis A.G., et al. Prognostic significance of tumor volume after radical prostatectomy: A multivariate analysis of pathological prognostic factors. Eur Urol 2003, 43:39-44.
28. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999, 281:1395-1400.
29. Tefilli M.V., Gheiler E.L., Tiguert R., et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 1998, 60(3 Pt 1):802-806.
30. Swanson G.P., Riggs M., Hermans M. Pathologic findings at radical prostatectomy: Risk factors for failure and death. Urol Oncol 2007, 25:110-114.
31. Swanson G.P., Basler J. Identifying patients for post-prostatectomy adjuvant therapy. J Cancer 2010, 2:1-19.
32. Epstein J.I., Partin A.W., Sauvageot J., et al. Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long term follow-up. Am J Surg Pathol 1996, 20:286-292.
33. Stephenson A.J., Wood D.P., Kattan M.W., et al. Location, extent, and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 2009, 182:1357-1363.
34. Karakiewicz P.I., Eastham J.A., Graefen M., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: Multi-institutional assessment of 5831 patients. Urology 2005, 66:1245-1250.
35. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167:528-534.
36. Swindle P., Eastham J.A., Ohori M., et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005, 174:903-907.
37. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997, 37:1043-1052.
38. Paulson D.F. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994, 152(5 Pt 2):1826-1830.
39. Pfitzenmaier J., Pahernik S., Tremmel T., et al. Positive surgical margins after radical prostatectomy: Do they have an impact on biochemical or clinical progression?. BJU Int 2008, 102:1413.
40. Cheng L., Darson M.F., Bergstralh E.J., et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999, 86:1775-1782.
41. Mann M.J., DeCastro G.J., Desai M., et al. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era. Urology 2008, 72:1203-1207.
42. Alkhateeb S., Alibhai S., Fleshner N., et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol 2010, 183:145-150.
43. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004, 172:910-914.
44. D'Amico A.V., Whittington R., Malkowicz S.B., et al. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: Implications on the use of adjuvant therapy. Urology 1996, 47:538-547.
45. Kausik S.J., Blute M.L., Sebo T.J., et al. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer 2002, 95:1215-1219.
46. Weldon V.E., Tavel F.R., Neuwirth H., et al. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995, 153:1565-1569.
47. Lowe B.A., Lieberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: Selecting the patient for adjuvant therapy. J Urol 1997, 158:1452-1456.
48. Simon M.A., Kim S., Soloway M.S. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol 2006, 175:140-144.
49. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins Experience. Urol Clin North Am 2001, 28:555-565.
50. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997, 24:395-406.
51. McAleer S.J., Schultz D., Whittington R., et al. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol 2005, 23:311-317.
52. Tefilli M.V., Gheiler E.L., Tiguert R., et al. Should Gleason score 7 prostate cancer be considered a unique grade category?. Urology 1999, 53:372-377.
53. Epstein J.I., Carmichael M., Partin A.W., et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 1993, 149:1478-1481.
54. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle, and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001, 165:119-125.
55. Kikuchi E., Scardino P.T., Wheeler T.M., et al. Is tumor volume an independent prognostic factor in clinically localized prostate cancer?. J Urol 2004, 172:508-511.
56. Ramos C.G., Roehl K.A., Antenor J.A., et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 2004, 172:137-140.
57. Marks R.A., Koch M.O., Lopez-Beltran A., et al. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol 2007, 38:1207-1211.
58. Presti J.C., Shinohara K., Bacchetti P., et al. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998, 52:1079-1084.
59. San Francisco I.F., Regan M.M., Olumi A.F., et al. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol 2004, 171:1492-1499.
60. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 2000, 18:3240-3246.
61. Jayachandran J., Bañez L.L., Levy D.E., et al. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: Results from the SEARCH database. J Urol 2008, 179:1791-1796. SEARCH Database Study Group.
62. Schroeck F.R., Kattan M.W., Moul J.W., et al. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int 2010, 105:1654-1659.
63. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005, 23:7005-7012.
64. Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999, 17:1499-1507.
65. Kattan M.W., Vickers A.J., Yu C., et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009, 115:1005-1010.
66. Walz J., Chun F.K., Klein E.A., et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009, 181:601.
67. Swanson G.P., Thompson I.M. Adjuvant radiotherapy for high-risk patients following radical prostatectomy. Urol Oncol 2007, 25:515-519.
68. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol 2009, 181:956-962.
69. Bolla M., van Poppel H., Collette L., et al. Postoperative Radiotherapy after Radical Prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578. European Organization for Research and Treatment of Cancer.
70. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
71. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: The Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol 2006, (17S10):59-62.
72. Sargent D., Sobrero A., Grothey A., et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009, 27:872-877.
73. Moinpour C.M., Hayden K.A., Unger J.M., et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008, 26:112-120. Southwest Oncology Group.
74. Djavan B., Milani S., Fong Y.K. Benign positive margins after radical prostatectomy means a poor prognosis. Urology 2005, 65:218-220.
75. Godoy G., Tareen B.U., Lepor H. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?. Urology 2009, 74:167-170.
76. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
77. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007, 177:540-545.
78. Shen S., Lepor H., Yaffee R., et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005, 173:777-780.
79. Trabulsi E.J., Valicenti R.K., Hanlon A.L., et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008, 72:1298-1302.
80. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25:2035-2041.
81. Swanson G.P., Du F., Michalek J.E., et al. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising PSA. Int J Radiat Oncol Biol Phys 2011, 80:62-68.
82. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008, 299:2760-2769.
83. Swanson G.P., Hussey M.A., Tangen C.M., et al. SWOG 8794. Predominant treatment failure in post-prostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007, 25:2225-2229.
84. Byar D.P., Corle D.K. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988, 7:165-170.
85. Dorff T.B., Flaig T.W., Tangen C.M., et al. Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. J Clin Oncol 2011, 29:2040-2045.
86. Saylor P.J., Smith M.R. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009, 181:1998-2006.
87. Iversen P., McLeod D.G., See W.A., et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: Final results from the bicalutamide Early Prostate Cancer Programme at a median follow-up of 9.7 years. (Report) BJU Int 2010, 105:1074.
88. Iversen P., Johansson J.E., Lodding P., et al. Bicalutamide (150 mg) vs. placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-Year median follow-up from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004, 172(5 Pt 1):1871-1876. Scandinavian Prostatic Cancer Group.